SCI Pharmtech (4119) Stock Overview
Engages in the research and development, manufacture, and sale of active pharmaceutical ingredients, intermediates, and specialty chemicals. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 4/6 |
| Dividends | 1/6 |
4119 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
SCI Pharmtech, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$44.75 |
| 52 Week High | NT$64.90 |
| 52 Week Low | NT$39.60 |
| Beta | 0.010 |
| 1 Month Change | 8.35% |
| 3 Month Change | -14.44% |
| 1 Year Change | -29.86% |
| 3 Year Change | -53.17% |
| 5 Year Change | -32.20% |
| Change since IPO | 125.63% |
Recent News & Updates
Recent updates
Shareholder Returns
| 4119 | TW Pharmaceuticals | TW Market | |
|---|---|---|---|
| 7D | -0.1% | 2.9% | 3.7% |
| 1Y | -29.9% | -7.5% | 106.2% |
Return vs Industry: 4119 underperformed the TW Pharmaceuticals industry which returned -7.5% over the past year.
Return vs Market: 4119 underperformed the TW Market which returned 106.2% over the past year.
Price Volatility
| 4119 volatility | |
|---|---|
| 4119 Average Weekly Movement | 3.9% |
| Pharmaceuticals Industry Average Movement | 4.8% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in TW Market | 12.1% |
| 10% least volatile stocks in TW Market | 2.6% |
Stable Share Price: 4119 has not had significant price volatility in the past 3 months compared to the TW market.
Volatility Over Time: 4119's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1987 | n/a | Wen-Chih Chou | www.sci-pharmtech.com.tw |
SCI Pharmtech, Inc. engages in the research and development, manufacture, and sale of active pharmaceutical ingredients, intermediates, and specialty chemicals. The company offers active pharmaceutical ingredients, including adenine, articaine HCl, atomoxetine HCl, bisoprolol hemifumarate, brinzolamide, buprenorphine and buprenorphine HCl, cannabidol, divalproex sodium, duloxetine HCl, hydroxychloroquine sulfate, loxoprofen sodium, methylphenidate HCl, pentobarbital sodium, pimobendan, probucol, propafenone HCI, sodium valproate, thiopental, and valproic acid; and develops benserazide, CBN, and CBDv. It also provides intermediate products, such as diethyl isobutyl malonate, benzhydrylamine, 1-Benzhydrylazetidin-3-ol, azetidin-3-ol hydrogenchloride, 1-(2-hydroxyphenyl)-3-phenylpropan-1-one, ritalinic acid, d-ritalinic acid HCl, pyrogallol aldehyde, menthadienol, 5-pentylbenzene-1,3-diol olivetol, methyl 2,4-dihydroxy-6-pentylbenzoate, ethyl 2,4-dihydroxy-6-pentylbenzoate ethyl olivetolate, divarinol, lisdexamfetamine intermediate, UDP-GIcNAz, and UDP-GaINAz.
SCI Pharmtech, Inc. Fundamentals Summary
| 4119 fundamental statistics | |
|---|---|
| Market cap | NT$5.35b |
| Earnings (TTM) | NT$95.75m |
| Revenue (TTM) | NT$1.36b |
Is 4119 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4119 income statement (TTM) | |
|---|---|
| Revenue | NT$1.36b |
| Cost of Revenue | NT$1.01b |
| Gross Profit | NT$354.19m |
| Other Expenses | NT$258.44m |
| Earnings | NT$95.75m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.80 |
| Gross Margin | 26.06% |
| Net Profit Margin | 7.04% |
| Debt/Equity Ratio | 19.2% |
How did 4119 perform over the long term?
See historical performance and comparisonDividends
Does 4119 pay a reliable dividends?
See 4119 dividend history and benchmarks| SCI Pharmtech dividend dates | |
|---|---|
| Ex Dividend Date | Jul 01 2026 |
| Dividend Pay Date | Aug 05 2026 |
| Days until Ex dividend | 7 days |
| Days until Dividend pay date | 28 days |
Does 4119 pay a reliable dividends?
See 4119 dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/07 19:21 |
| End of Day Share Price | 2026/07/07 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
SCI Pharmtech, Inc. is covered by 4 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yu-Ying Yang | KGI Securities Co. Ltd. |
| Xiaowei Huang | Masterlink Securities Investment Advisory |
| Yijun Chen | SinoPac Securities Investment Service |